Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Rating of “Moderate Buy” from Analysts

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) has been assigned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $55.2857.

Several research analysts recently issued reports on KNSA shares. Weiss Ratings reissued a “hold (c)” rating on shares of Kiniksa Pharmaceuticals International in a research note on Thursday, January 22nd. Wells Fargo & Company lifted their price target on shares of Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Zacks Research upgraded shares of Kiniksa Pharmaceuticals International from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Canaccord Genuity Group began coverage on shares of Kiniksa Pharmaceuticals International in a research report on Thursday, February 19th. They set a “buy” rating and a $62.00 price objective on the stock. Finally, Wedbush raised their target price on Kiniksa Pharmaceuticals International from $50.00 to $53.00 and gave the company an “outperform” rating in a research note on Wednesday, February 25th.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA opened at $46.16 on Monday. Kiniksa Pharmaceuticals International has a 52-week low of $18.25 and a 52-week high of $49.12. The business’s 50 day moving average price is $43.32 and its two-hundred day moving average price is $40.32. The firm has a market cap of $3.53 billion, a PE ratio of 62.38 and a beta of 0.06.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $0.17 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.29 by ($0.12). The business had revenue of $202.13 million for the quarter, compared to the consensus estimate of $200.86 million. Kiniksa Pharmaceuticals International had a return on equity of 11.48% and a net margin of 8.71%.Kiniksa Pharmaceuticals International’s quarterly revenue was up 65.0% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.12) earnings per share. Research analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 12,048 shares of the firm’s stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $41.56, for a total value of $500,714.88. Following the completion of the sale, the chief operating officer owned 16,666 shares of the company’s stock, valued at approximately $692,638.96. This trade represents a 41.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Mark Ragosa sold 17,845 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $43.28, for a total value of $772,331.60. Following the completion of the sale, the chief financial officer directly owned 12,086 shares of the company’s stock, valued at $523,082.08. This trade represents a 59.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 80,782 shares of company stock worth $3,458,916. Corporate insiders own 53.48% of the company’s stock.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently bought and sold shares of the business. Mark Sheptoff Financial Planning LLC boosted its stake in shares of Kiniksa Pharmaceuticals International by 1.6% in the 4th quarter. Mark Sheptoff Financial Planning LLC now owns 16,350 shares of the company’s stock worth $674,000 after buying an additional 250 shares during the last quarter. Mariner LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.0% during the fourth quarter. Mariner LLC now owns 13,519 shares of the company’s stock valued at $558,000 after acquiring an additional 266 shares during the last quarter. Virtus Investment Advisers LLC increased its position in shares of Kiniksa Pharmaceuticals International by 2.5% during the fourth quarter. Virtus Investment Advisers LLC now owns 16,432 shares of the company’s stock valued at $678,000 after acquiring an additional 406 shares during the last quarter. Mercer Global Advisors Inc. ADV lifted its holdings in Kiniksa Pharmaceuticals International by 7.1% during the fourth quarter. Mercer Global Advisors Inc. ADV now owns 7,684 shares of the company’s stock worth $317,000 after acquiring an additional 508 shares during the period. Finally, EverSource Wealth Advisors LLC lifted its holdings in Kiniksa Pharmaceuticals International by 140.4% during the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the period. Institutional investors and hedge funds own 53.95% of the company’s stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1β blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.